<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454788</url>
  </required_header>
  <id_info>
    <org_study_id>2019.125</org_study_id>
    <nct_id>NCT04454788</nct_id>
  </id_info>
  <brief_title>Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion</brief_title>
  <acronym>ETERNAL-LVO</acronym>
  <official_title>Extending the Time Window for Tenecteplase by Effective Reperfusion of peNumbrAL Tissue in Patients With Large Vessel Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Professor Mark Parsons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Melbourne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting to the emergency department with an acute ischemic stroke due to a large&#xD;
      vessel occlusion eligible for thrombectomy and target mismatch on computed tomography&#xD;
      perfusion imaging within 24 hours of onset will be assessed determine their eligibility for&#xD;
      randomization into the trial. If the patient gives informed consent they will be randomised&#xD;
      using a central computerised allocation process to either standard of care (no intravenous&#xD;
      thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing&#xD;
      intra-arterial clot retrieval. The trial is prospective, randomised, open-label, blinded&#xD;
      endpoint (PROBE) design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS (if baseline premorbid mRS =2) at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early clinical improvement</measure>
    <time_frame>24 hours</time_frame>
    <description>Reduction in National Institutes of Health Stroke Scale (NIHSS) score of ≥8 points at 24 hours or reaching NIHSS 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) 0-2 (functional independence)</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS) 0-2 (functional independence) at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substantial reperfusion at initial angiographic assessment</measure>
    <time_frame>initial angiography within 24 hours of stroke onset</time_frame>
    <description>Proportion of patients with &gt;50% reperfusion of the affected vascular territory (mTICI 3b/3) on initial digital subtraction angiography prior to thrombectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral hemorrhage (sICH)</measure>
    <time_frame>24 hours post-randomization</time_frame>
    <description>sICH defined as parenchymal hematoma type 2 (PH2) - blood clot occupying &gt;30% of the infarcted territory with substantial mass effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) 5-6</measure>
    <time_frame>90 days</time_frame>
    <description>Poor functional outcome of death or requirement for fulltime nursing care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful reperfusion at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Reperfusion (defined as &gt;90% and &gt;50% reduction in perfusion lesion volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>24 hours</time_frame>
    <description>Increase in the volume of irreversibly injured brain between pre-treatment and 24 hour imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalization</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in vessel patency between pre-treatment and 24h imaging (CT or MR angiography)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intravenous tenecteplase (TNK)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous tissue plasminogen activator (tPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds</description>
    <arm_group_label>Intravenous tenecteplase (TNK)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care (which may include intravenous Alteplase)</intervention_name>
    <description>Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.</description>
    <arm_group_label>Intravenous tissue plasminogen activator (tPA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with acute hemispheric ischemic stroke with onset (or the time&#xD;
             they last known to be well) within 24 hours.&#xD;
&#xD;
          -  Patient's age is ≥18 years.&#xD;
&#xD;
          -  Premorbid mRS &lt;3, with a concurrent assessment of whether the patient was able,&#xD;
             immediately prior to the stroke, to: 1) Drive, or (if never drives) perform own&#xD;
             Domestic duties, and 2) Shop for themselves, and 3) Bank/do their own finances (i.e.&#xD;
             Drive/Domestic, Bank, Shop = DBS +ve). Need to be DBS +ve to be study eligible.&#xD;
&#xD;
          -  Presence of a vessel occlusion on CTA or MRA. LVO will be defined as 'potentially&#xD;
             retrievable' thrombus at one or more of the following sites: intracranial internal&#xD;
             carotid (ICA), middle cerebral artery (MCA) first segment (M1), proximal middle&#xD;
             cerebral artery second segment (M2) or isolated/tandem occlusion of the extracranial&#xD;
             ICA. Patients with an extracranial ICA stenosis and occlusion are also eligible.&#xD;
&#xD;
          -  Presence of 'target mismatch' on automated perfusion CT (CTP) or diffusion-perfusion&#xD;
             MRI software defined as an ischemic core of &lt;70mL, penumbra of &gt;20mL and an ischemic&#xD;
             core to perfusion lesion ratio of &gt;1.8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracranial hemorrhage (ICH) or other diagnosis (e.g. tumor).&#xD;
&#xD;
          -  Basilar Artery occlusion.&#xD;
&#xD;
          -  Extensive early ischemic change (hypodensity on NCCT or high signal on DWI-MRI) or&#xD;
             early ischemic change outside the perfusion lesion that invalidates mismatch criteria.&#xD;
&#xD;
          -  Pre-stroke mRS score of &gt; 2 (indicating significant previous disability) or DBS -ve.&#xD;
&#xD;
          -  Any terminal illness such that patient would not be expected to survive more than 1&#xD;
             year&#xD;
&#xD;
          -  Any condition that, in the judgment of the investigator could impose hazards to the&#xD;
             patient if study therapy is initiated or affect the participation of the patient in&#xD;
             the study.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Other standard contraindications to thrombolysis.&#xD;
&#xD;
          -  Minor stroke symptoms, or major stroke symptoms rapidly improving&#xD;
&#xD;
          -  Clinical presentation suggesting subarachnoid haemorrhage&#xD;
&#xD;
          -  Known bleeding diasthesis and/or platelet count &lt;100,000 or taking warfarin with INR &gt;&#xD;
             1.7.&#xD;
&#xD;
          -  Patients who have received heparin within 48 hours must have normal aPTT.&#xD;
&#xD;
          -  Major surgery or serious trauma within 14 days, serious head trauma within 3 months.&#xD;
&#xD;
          -  GI or urinary tract haemorrhage within last 21 days&#xD;
&#xD;
          -  Arterial puncture at a non-compressible site or lumbar puncture within 7 days&#xD;
&#xD;
          -  Systolic BP &gt; 185, diastolic BP &gt; 110mmHg&#xD;
&#xD;
          -  Clinical stroke within 3 months or history of ICH&#xD;
&#xD;
          -  Unable to gain consent from patient or person responsible&#xD;
&#xD;
          -  Known severe renal impairment (GFR &lt; 15mls/min)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Bivard, PHD</last_name>
    <phone>+6193424424</phone>
    <email>abivard@unimelb.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy McDonald, BN</last_name>
    <phone>+6193424424</phone>
    <email>amym1@unimelb.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Cordato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Russell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Butcher</last_name>
      <email>ken.butcher@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba 4102</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Brown</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Kleinig</last_name>
      <email>tim.kleinig@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy McDonald</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Choi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Melbourne</investigator_affiliation>
    <investigator_full_name>Bruce Campbell</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

